Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 8/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11739938 | 1.00 | LSS (0.34) | LSSCNR2 | |
| SCHEMBL310618 | 0.83 | LSS (0.35) | LSSCNR2 | |
| SCHEMBL14518213 | 0.83 | LSS (0.35) | LSSCNR2 | |
| SCHEMBL15164669 | 0.83 | LSS (0.35) | LSSCNR2 | |
| SCHEMBL9650230 | 0.83 | LSS (0.35) | LSSCNR2 | |
| SCHEMBL11001883 | 0.83 | LSS (0.35) | LSSCNR2 | |
| SCHEMBL10629087 | 0.83 | LSS (0.35) | LSSCNR2 | |
| SCHEMBL17706519 | 0.81 | LSS (0.34) | LSSCNR2 | |
| SCHEMBL11342582 | 0.81 | LSS (0.34) | LSSCNR2 | |
| SCHEMBL17705183 | 0.81 | LSS (0.34) | LSSCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3649133-B1 | ENGLERIN DERIVATIVES FOR TREATMENT OF CANCER | US HEALTH (US) | 2022-02-23 | — | — | EP | disclosed |
| US-20200140451-A1 | ENGLERIN DERIVATIVES FOR TREATMENT OF CANCER | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-05-07 | — | — | US | disclosed |
| US-20200140451-A1 | ENGLERIN DERIVATIVES FOR TREATMENT OF CANCER | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-05-07 | — | — | US | disclosed |
| EP-3283489-B1 | EPOXYAZULENE DERIVATIVES USEFUL FOR TREATING CANCER | US HEALTH (US) | 2019-08-21 | — | — | EP | disclosed |
| US-10287297-B2 | Epoxyazulene derivatives useful for treating cancer and diabetes | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2019-05-14 | — | — | US | disclosed |
| WO-2019010298-A1 | ENGLERIN DERIVATIVES FOR TREATMENT OF CANCER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2019-01-10 | — | — | WO | disclosed |
| US-20180127433-A1 | EPOXYAZULENE DERIVATIVES USEFUL FOR TREATING CANCER AND DIABETES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN (US) | 2018-05-10 | — | — | US | disclosed |
| US-20180127433-A1 | EPOXYAZULENE DERIVATIVES USEFUL FOR TREATING CANCER AND DIABETES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN (US) | 2018-05-10 | — | — | US | disclosed |
| WO-2016168281-A1 | EPOXYAZULENE DERIVATIVES USEFUL FOR TREATING CANCER AND DIABETES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10287297-B2 | Epoxyazulene derivatives useful for treating cancer and diabetes | ESRRA, ESRRB, ESRRG | LSS 739/4885CNR2 1429/4885 |
| US-20180127433-A1 | EPOXYAZULENE DERIVATIVES USEFUL FOR TREATING CANCER AND DIABETES | ESRRA, ESRRB, ESRRG | LSS 739/4885CNR2 1429/4885 |
| US-20200140451-A1 | ENGLERIN DERIVATIVES FOR TREATMENT OF CANCER | XPO5, ATP6V1B1, ENTPD5 | LSS 2603/4885CNR2 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.